Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Intellia Therapeutics, Inc. (NTLA)  
$24.46 0.40 (1.61%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 89,554,000
Market Cap: 2.19(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $20.02 - $46.03
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 2,902 53,430 61,187 62,275
Total Sell Value $95,737 $1,583,155 $1,913,663 $1,961,404
Total People Sold 2 7 8 8
Total Sell Transactions 2 10 15 16
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 245
  Page 4 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-11-05 4 OE $12.62 $30,288 D/D 2,400 11,114     -
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-10-14 4 AS $126.92 $308,249 D/D (2,400) 8,714 -27%     
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-10-14 4 OE $12.62 $30,288 D/D 2,400 11,114     -
   Crowley John F Director   –       •      –    2021-10-11 4 AS $119.55 $298,875 D/D (2,500) 2,094 -33%     
   Crowley John F Director   –       •      –    2021-10-11 4 OE $18.83 $47,075 D/D 2,500 4,594     -
   Crowley John F Director   –       •      –    2021-10-05 4 AS $128.83 $1,305,391 D/D (10,000) 2,094 -24%     
   Crowley John F Director   –       •      –    2021-10-05 4 OE $18.83 $188,300 D/D 10,000 12,094     -
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-09-24 4 OE $12.62 $99,988 D/D 7,923 8,714     -
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-09-21 4 AS $149.81 $359,544 D/D (2,400) 791 -32%     
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-09-21 4 OE $12.62 $30,288 D/D 2,400 3,191     -
   Goddard Glenn EVP, Chief Financial Officer   •       –      –    2021-09-07 4 AS $180.12 $627,178 D/D (3,482) 0 -47%     
   Goddard Glenn EVP, Chief Financial Officer   •       –      –    2021-09-07 4 OE $14.58 $50,768 D/D 3,482 3,482     -
   Leonard John M. President and CEO   •       •      –    2021-09-01 4 AS $170.00 $7,604,950 D/D (44,735) 719,305 -40%     
   Leonard John M. President and CEO   •       •      –    2021-09-01 4 OE $18.30 $967,001 D/D 44,735 764,040     -
   Leonard John M. President and CEO   •       •      –    2021-08-31 4 AS $155.00 $5,864,115 D/D (37,833) 719,305 -34%     
   Leonard John M. President and CEO   •       •      –    2021-08-31 4 OE $14.58 $551,605 D/D 37,833 757,138     -
   Goddard Glenn EVP, Chief Financial Officer   •       –      –    2021-08-31 4 AS $160.22 $3,973,456 D/D (24,800) 0 -34%     
   Goddard Glenn EVP, Chief Financial Officer   •       –      –    2021-08-31 4 OE $14.58 $469,374 D/D 24,800 24,800     -
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-08-30 4 AS $155.43 $379,300 D/D (2,400) 791 -32%     
   Lebwohl David EVP, Chief Medical Officer   •       –      –    2021-08-30 4 OE $12.62 $30,288 D/D 2,400 3,191     -
   Leonard John M. President and CEO   •       •      –    2021-08-30 4 AS $152.81 $6,051,353 D/D (38,804) 719,305 -32%     
   Leonard John M. President and CEO   •       •      –    2021-08-30 4 OE $13.40 $552,031 D/D 38,804 758,109     -
   Sepp-Lorenzino Laura EVP, Chief Scientific Officer   •       –      –    2021-08-30 4 AS $152.75 $15,018,054 D/D (97,000) 2,391 -32%     
   Sepp-Lorenzino Laura EVP, Chief Scientific Officer   •       –      –    2021-08-30 4 OE $13.40 $1,359,300 D/D 97,000 99,391     -
   Goddard Glenn EVP, Chief Financial Officer   •       –      –    2021-08-30 4 AS $153.22 $810,082 D/D (5,200) 0 -32%     
  245 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us